Background In vivo efficacy assessments of antimalarials are essential for ensuring effective
case management. In Ethiopia, chloroquine (CQ) without primaquine is the first-line …

Background Ethiopia is one of the few countries in Africa where Plasmodium vivax
commonly co-exists with Plasmodium falciparum, and which accounts for~ 40% of the total …

Background Recent efforts in malaria control have resulted in great gains in reducing the
burden of Plasmodium falciparum, but P. vivax has been more refractory. Its ability to form …

Abstract Background In Guyana, chloroquine+ primaquine is used for the treatment of vivax
malaria. A worldwide increase of chloroquine resistance in Plasmodium vivax led to …

Background Plasmodium vivax accounts for about 44% of all malaria infection in Ethiopia.
Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia. Chloroquine …

Background Plasmodium vivax malaria is still an important public health problem in
Ethiopia. Unlike Plasmodium falciparum, P. vivax has a dormant liver stage (hypnozoite) that …

Plasmodium vivax is the second most important cause of morbidity in Ethiopia. There is,
however, little information on P. vivax resistance to chloroquine and chloroquine plus …

Background Declining efficacy of chloroquine for the treatment Plasmodium vivax malaria
has been reported in different endemic settings in Ethiopia. This highlights the need to …

Background Afghanistan's national guidelines recommend chloroquine for the treatment of
Plasmodium vivax infection, the parasite responsible for the majority of its malaria burden …

Nearly 40% of all malaria infection in Ethiopia is caused by Plasmodium vivax. Chloroquine
(CQ) is the first line treatment for confirmed P. vivax malaria in the country. However, the …